Entresto® (sacubitril/valsartan) – Expanded indication
February 16, 2021 - Novartis announced the FDA approval of Entresto (sacubitril/valsartan), to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adult patients with chronic heart failure (CHF). Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.
Top